We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+12.76%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$478M
AUM Growth
+$56.7M
Cap. Flow
+$17.4M
Cap. Flow %
3.64%
Top 10 Hldgs %
53.49%
Holding
96
New
7
Increased
25
Reduced
16
Closed
12

Top Buys

Rank Stock Value
1
TBPH icon
Theravance Biopharma
TBPH
+$13M
2
FSTX
F-star Therapeutics, Inc. Common Stock
FSTX
+$6.09M
3
OTIC
Otonomy, Inc.
OTIC
+$4.6M
4
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$2.98M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$2.8M

Top Sells

Rank Stock Value
1
PLX icon
Protalix BioTherapeutics
PLX
+$5.37M
2
ATRC icon
AtriCure
ATRC
+$2.69M
3
ALEC icon
Alector
ALEC
+$2.57M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$2.36M
5
AGTC
Applied Genetic Technologies Corporation
AGTC
+$2.18M

Sector Composition

Rank Sector Weight
1 Healthcare 90.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IFRX icon
51
InflaRx
IFRX
$258M
$1.78M 0.37%
600,000
– –
ACRS icon
52
Aclaris Therapeutics
ACRS
$772M
$1.76M 0.37%
+100,000
New +$2.27M
KURA icon
53
Kura Oncology
KURA
$816M
$1.74M 0.36%
83,529
+31,729
+61% +$788K
MRSN
54
DELISTED
Mersana Therapeutics
MRSN
$1.74M 0.36%
5,131
+160
+3% +$60.6K
CGEN icon
55
Compugen
CGEN
$225M
$1.67M 0.35%
201,502
+12,500
+7% +$101K
LONA
56
LeonaBio Inc
LONA
$70.2M
$1.65M 0.34%
16,098
+6,945
+76% +$1.21M
STRO icon
57
Sutro Biopharma
STRO
$416M
$1.58M 0.33%
8,500
– –
BOLT icon
58
Bolt Biotherapeutics
BOLT
$7.65M
$1.55M 0.32%
+5,000
New +$2.03M
KDMN
59
DELISTED
Kadmon Holdings, Inc.
KDMN
$1.53M 0.32%
394,561
– –
CFMS
60
DELISTED
Conformis, Inc. Common Stock
CFMS
$1.5M 0.31%
52,000
– –
LVTX
61
DELISTED
LAVA Therapeutics
LVTX
$1.48M 0.31%
+135,632
New +$1.68M
NXTC icon
62
NextCure
NXTC
$17.9M
$1.47M 0.31%
15,291
+9,874
+182% +$1.01M
HARP
63
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$1.46M 0.31%
10,516
-2,150
-17% -$410K
KALV
64
DELISTED
KalVista Pharmaceuticals
KALV
$1.45M 0.3%
60,600
+2,000
+3% +$52.3K
INFI
65
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.37M 0.29%
459,260
– –
KNTE
66
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$1.27M 0.27%
54,415
+1,500
+3% +$38.2K
ISEE
67
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.14M 0.24%
179,951
+90,000
+100% +$581K
RIGL icon
68
Rigel Pharmaceuticals
RIGL
$693M
$1.06M 0.22%
24,400
-3,150
-11% -$119K
ALPN
69
DELISTED
Alpine Immune Sciences Inc
ALPN
$1.02M 0.21%
113,302
– –
INGN icon
70
Inogen
INGN
$182M
$978K 0.2%
15,000
– –
ASND icon
71
Ascendis Pharma A/S
ASND
$16B
$939K 0.2%
7,137
-16,100
-69% -$2.15M
SRGA
72
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$806K 0.17%
+19,324
New +$990K
APLS
73
DELISTED
Apellis Pharmaceuticals
APLS
$803K 0.17%
12,703
-32,223
-72% -$1.66M
LRMR icon
74
Larimar Therapeutics
LRMR
$413M
$756K 0.16%
76,987
-4,445
-5% -$50.2K
NTBL
75
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$734K 0.15%
+8,771
New +$665K
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, DAFNA Capital Management held 96 positions worth $478M, up 13% from $421M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

DAFNA Capital Management deployed $17.4M of net new capital in Q2 2021, opening 7 new positions and adding to 25 existing holdings. Its largest new stake was F-star Therapeutics, Inc. Common Stock: 714,285 shares worth $6.14M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 91% a quarter earlier.

On the sell side, the largest reduction was AtriCure, an estimated $2.69M trimmed.

  • DAFNA Capital Management's largest Q2 2021 buy was F-star Therapeutics, Inc. Common Stock: 714,285 shares worth $6.14M.
  • DAFNA Capital Management added most to Theravance Biopharma in Q2 2021, an estimated $13M increase.
  • DAFNA Capital Management's biggest Q2 2021 reduction was AtriCure, cutting an estimated $2.69M.
  • DAFNA Capital Management fully exited Protalix BioTherapeutics in Q2 2021, selling an estimated $5.37M.
  • DAFNA Capital Management's ten largest holdings make up 53% of its $478M portfolio in Q2 2021.
  • DAFNA Capital Management opened 7 new positions and closed 12 in Q2 2021.
  • DAFNA Capital Management's portfolio value rose 13% quarter-over-quarter to $478M.

Based on DAFNA Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.